Clinical Trials and Research

For the latest episode of the JNC CardioConnect podcast, Marcelo F. Di Carli, MD, MASNC, brought together 4 experts for a conversation about where the field of…

AbstractEarly diagnosis and accurate monitoring of disease progression are crucial for timely therapeutic intervention in hereditary transthyretin amyloidosis (…

FDA Grants Orphan Drug Designation to Zamubafusp AlfaAttralus, a clinical-stage biopharmaceutical company focused on systemic amyloidosis, has announced an…

Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is a microangiopathy driven by the thromboinflammation of capillary beds and angiogenic revascularization…

Researchers have identified a common structure among toxic transthyretin (TTR) clumps, called amyloid fibrils, in heart tissue from people carrying mutations linked…

Cardiac amyloidosis, particularly transthyretin amyloidosis (ATTR) in older adults, is increasingly recognized as an important and potentially treatable cause of…

Background: Cardiac amyloidosis (CA) is an infiltrative restrictive cardiomyopathy characterized by the deposition of β-fold amyloid, often presenting as left…

ABSTRACTBackground and AimsHereditary transthyretin amyloidosis (ATTRv) is a multisystemic disease where early neuropathy signs are challenging to detect…

AbstractThe management of transthyretin amyloid cardiomyopathy (ATTR-CM) has revolved around the scintigraphic diagnosis since the introduction of a specific…

The safety and efficacy of vutrisiran are consistent with those observed in the overall population of East Asian patients treated in the phase 3 clinical trial…